Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes

Journal of Cardiology

Volumn 62, Issue 3, 2013, Pages 158-164

  Nagashima, Zenko ^a   Tsukahara, Kengo ^a   Morita, Satoshi ^b   Endo, Tsutomu ^c   Sugano, Teruyasu ^b   Hibi, Kiyoshi ^a   Himeno, Hideo ^d   Fukui, Kazuki ^e   Umemura, Satoshi ^b   Kimura, Kazuo ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Saiseikai Yokohama City Southern Hospital   (Japan)

^d Fujisawa City Hospital   (Japan)

^e Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

Coronary heart disease; Genetics; Platelet inhibitors; Stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; FAMOTIDINE; OMEPRAZOLE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIAC PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY STENT; DRUG MEGADOSE; FEMALE; HUMAN; IMPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PLATELET REACTIVITY; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

CORONARY HEART DISEASE; GENETICS; PLATELET INHIBITORS; STENT;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RECEPTORS, PURINERGIC P2Y12; STENTS; TICLOPIDINE;

EID: 84883555530     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.03.006     Document Type: Article

References (45)

1. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
2. Steinhubl S.R., Berger P.B., Mann J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
3. Tsukahara K., Kimura K., Morita S., Ebina T., Kosuge M., Hibi K., Iwahashi N., Endo M., Maejima N., Sugano T., Umemura S. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J Cardiol 2011, 57:275-282.
4. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007, 49:657-666.
5. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
6. De Morais S.M., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994, 46:594-598.
7. de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994, 269:15419-15422.
8. Jeong Y.H., Tantry U.S., Kim I.S., Koh J.S., Kwon T.J., Park Y., Hwang S.J., Bliden K.P., Kwak C.H., Hwang J.Y., Gurbel P.A. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in east Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011, 4:585-594.
9. Yamamoto K., Hokimoto S., Chitose T., Morita K., Ono T., Kaikita K., Tsujita K., Abe T., Deguchi M., Miyagawa H., Saruwatari J., Sumida H., Sugiyama S., Nakagawa K., Ogawa H. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011, 57:194-201.
10. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T., Deneer V.H., Harmsze A.M., van der Heyden J.A., Rensing B.J., Suttorp M.J., Hackeng C.M., ten Berg J.M. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
11. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., Buonamici P., Antoniucci D., Abbate R., Gensini G.F. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
12. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133.
13. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
14. Brar S.S., ten Berg J., Marcucci R., Price M.J., Valgimigli M., Kim H.S., Patti G., Breet N.J., DiSciascio G., Cuisset T., Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011, 58:1945-1954.
15. Malinin A., Pokov A., Spergling M., Defranco A., Schwartz K., Schwartz D., Mahmud E., Atar D., Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007, 119:277-284.
16. Nielsen H.L., Kristensen S.D., Thygesen S.S., Mortensen J., Pedersen S.B., Grove E.L., Hvas A.M. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008, 123:267-273.
17. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913-958.
18. Sugimoto K., Uno T., Yamazaki H., Tateishi T. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008, 65:437-439.
19. Thygesen K., Alpert J.S., White H.D., Jaffe A.S., Apple F.S., Galvani M., Katus H.A., Newby L.K., Ravkilde J., Chaitman B., Clemmensen P.M., Dellborg M., Hod H., Porela P., Underwood R., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
20. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
21. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., Keren G., Carr J., Cohen E.A., Betriu A., Desmet W., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003, 289:853-863.
22. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
23. Mega J.L., Simon T., Collet J.P., Anderson J.L., Antman E.M., Bliden K., Cannon C.P., Danchin N., Giusti B., Gurbel P., Horne B.D., Hulot J.S., Kastrati A., Montalescot G., Neumann F.J., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
24. Mehta S.R., Tanguay J.F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., Faxon D.P., Rupprecht H.J., Budaj A., Avezum A., Widimsky P., Steg P.G., Bassand J.P., Montalescot G., Macaya C., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
25. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
26. Wallentin L., James S., Storey R.F., Armstrong M., Barratt B.J., Horrow J., Husted S., Katus H., Steg P.G., Shah S.H., Becker R.C. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010, 376:1320-1328.
27. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramirez C., Sabate M., Jimenez-Quevedo P., Hernandez R., Moreno R., Escaned J., Alfonso F., Banuelos C., Costa M.A., Bass T.A., Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
28. Desai N.R., Mega J.L., Jiang S., Cannon C.P., Sabatine M.S. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009, 53:1273-1278.
29. Mega J.L., Hochholzer W., Frelinger A.L., Kluk M.J., Angiolillo D.J., Kereiakes D.J., Isserman S., Rogers W.J., Ruff C.T., Contant C., Pencina M.J., Scirica B.M., Longtine J.A., Michelson A.D., Sabatine M.S. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011, 306:2221-2228.
30. Park K.W., Park J.J., Lee S.P., Oh I.Y., Suh J.W., Yang H.M., Lee H.Y., Kang H.J., Cho Y.S., Koo B.K., Youn T.J., Chae I.H., Choi D.J., Oh B.H., Park Y.B., et al. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. Heart 2011, 97:641-647.
31. Cuisset T., Quilici J., Cohen W., Fourcade L., Saut N., Pankert M., Gaborit B., Carrieri P., Morange P.E., Bonnet J.L., Alessi M.C. Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. Am J Cardiol 2011, 108:760-765.
32. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W.L., Braunwald E., Sabatine M.S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
33. Ogawa H., Hokimoto S., Kaikita K., Yamamoto K., Chitose T., Ono T., Tsujita K. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. J Cardiol 2011, 58:6-17.
34. Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillabower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
35. Trenk D., Stone G.W., Gawaz M., Kastrati A., Angiolillo D.J., Muller U., Richardt G., Jakubowski J.A., Neumann F.J. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012, 59:2159-2164.
36. Collet J.P., Cuisset T., Range G., Cayla G., Elhadad S., Pouillot C., Henry P., Motreff P., Carrie D., Boueri Z., Belle L., Van Belle E., Rousseau H., Aubry P., Monsegu J., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012, 367:2100-2109.
37. Holmes M.V., Perel P., Shah T., Hingorani A.D., Casas J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011, 306:2704-2714.
38. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H., Nishikawa H., Hiasa Y., Muramatsu T., Meguro T., Inoue N., Honda H., Hayashi Y., Miyazaki S., Oshima S., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009, 119:987-995.
39. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
40. Gorog D.A., Yamamoto J., Saraf S., Ishii H., Ijiri Y., Ikarugi H., Wellsted D.M., Mori M., Yamori Y. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the "Japanese paradox". Int J Cardiol 2011, 152:43-48.
41. Tantry U.S., Bliden K.P., Suarez T.A., Kreutz R.P., Dichiara J., Gurbel P.A. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets 2010, 21:360-367.
42. Kimura T., Morimoto T., Kozuma K., Honda Y., Kume T., Aizawa T., Mitsudo K., Miyazaki S., Yamaguchi T., Hiyoshi E., Nishimura E., Isshiki T. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010, 122:52-61.
43. Suh J.W., Lee S.P., Park K.W., Lee H.Y., Kang H.J., Koo B.K., Cho Y.S., Youn T.J., Chae I.H., Choi D.J., Rha S.W., Bae J.H., Kwon T.G., Bae J.W., Cho M.C., et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011, 57:280-289.
44. Ahn S.G., Lee S.H., Yoon J.H., Kim W.T., Lee J.W., Youn Y.J., Ahn M.S., Kim J.Y., Yoo B.S., Yoon J., Choe K.H. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012, 5:259-267.
45. Parodi G., Marcucci R., Valenti R., Gori A.M., Migliorini A., Giusti B., Buonamici P., Gensini G.F., Abbate R., Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223.